{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:31:05Z","timestamp":1767929465689,"version":"3.49.0"},"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131861","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T17:38:07Z","timestamp":1436290687000},"page":"e0131861","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration"],"prefix":"10.1371","volume":"10","author":[{"given":"Rana","family":"Rais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minae","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marigo","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Alt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Giroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"JR Mesters","year":"2006","journal-title":"EMBO J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bst0280297","article-title":"l-glutamate as a central neurotransmitter: looking back","volume":"28","author":"JC Watkins","year":"2000","journal-title":"Biochem Soc Trans"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1471-4892(01)00009-1","article-title":"Amino acids are still as exciting as ever","volume":"1","author":"KJ Carpenter","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/70971","article-title":"Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury","volume":"5","author":"BS Slusher","year":"1999","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2174\/092986712799034888","article-title":"Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer","volume":"19","author":"C Barinka","year":"2012","journal-title":"Curr Med Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.2000.0750443.x","article-title":"N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system","volume":"75","author":"JH Neale","year":"2000","journal-title":"J Neurochem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2012.01.007","article-title":"mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia","volume":"136","author":"RT Olszewski","year":"2012","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/jpet.109.152553","article-title":"The neuroactive peptide N-acetylaspartylglutamate is not an agonist at the metabotropic glutamate receptor subtype 3 of metabotropic glutamate receptor","volume":"330","author":"M Chopra","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1471-4159.2011.07380.x","article-title":"N-acetylaspartylglutamate is an agonist at mGluR(3) in vivo and in vitro","volume":"119","author":"JH Neale","year":"2011","journal-title":"Journal of neurochemistry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2004.12.008","article-title":"Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats","volume":"508","author":"JB Long","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/neu.2005.22.266","article-title":"NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats","volume":"22","author":"C Zhong","year":"2005","journal-title":"J Neurotrauma"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1471-4159.2006.03786.x","article-title":"NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat","volume":"97","author":"C Zhong","year":"2006","journal-title":"J Neurochem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1021\/jm0001774","article-title":"Design and pharmacological activity of phosphinic acid based NAALADase inhibitors","volume":"44","author":"PF Jackson","year":"2001","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents","volume":"47","author":"AP Kozikowski","year":"2004","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1124\/jpet.300.2.662","article-title":"Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain","volume":"300","author":"SR Chen","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0006-8993(01)02650-6","article-title":"Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat","volume":"909","author":"T Yamamoto","year":"2001","journal-title":"Brain Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0306-4522(00)00502-9","article-title":"Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test","volume":"102","author":"T Yamamoto","year":"2001","journal-title":"Neuroscience"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jns.2006.05.052","article-title":"The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy","volume":"247","author":"W Zhang","year":"2006","journal-title":"J Neurol Sci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1460-9568.2004.03504.x","article-title":"Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model","volume":"20","author":"T Yamamoto","year":"2004","journal-title":"Eur J Neurosci"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1460-9568.2006.05272.x","article-title":"Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats","volume":"25","author":"T Yamamoto","year":"2007","journal-title":"Eur J Neurosci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1744-8069-6-60","article-title":"Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity\/transmission in the amygdala in a mouse inflammatory pain model","volume":"6","author":"MO Adedoyin","year":"2010","journal-title":"Mol Pain"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.npep.2003.08.001","article-title":"Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat","volume":"37","author":"KJ Carpenter","year":"2003","journal-title":"Neuropeptides"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.neuropharm.2006.07.018","article-title":"Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain\u2014relation to brain concentration","volume":"51","author":"J Nagel","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/aur.4","article-title":"Children with autism demonstrate circumscribed attention during passive viewing of complex social and nonsocial picture arrays","volume":"1","author":"NJ Sasson","year":"2008","journal-title":"Autism Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1744-8069-4-31","article-title":"Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain","volume":"4","author":"T Yamamoto","year":"2008","journal-title":"Mol Pain"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-510X(01)00670-0","article-title":"GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB\/Wor rats","volume":"194","author":"W Zhang","year":"2002","journal-title":"J Neurol Sci"},{"key":"ref27","first-page":"891","article-title":"Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain","volume":"53","author":"O Saito","year":"2006","journal-title":"Can J Anaesth"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1073\/pnas.1530168100","article-title":"Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models","volume":"100","author":"GD Ghadge","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1471-4159.2004.02358.x","article-title":"NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR","volume":"89","author":"RT Olszewski","year":"2004","journal-title":"J Neurochem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1471-4159.2003.02321.x","article-title":"Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3","volume":"89","author":"A Berent-Spillson","year":"2004","journal-title":"Journal of neurochemistry"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12640-009-9114-1","article-title":"Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat","volume":"17","author":"VA Carozzi","year":"2010","journal-title":"Neurotoxicity research"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1369-1600.2000.tb00209.x","article-title":"NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats","volume":"5","author":"DL McKinzie","year":"2000","journal-title":"Addiction biology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1098-2396(200011)38:2<161::AID-SYN7>3.0.CO;2-G","article-title":"Modulation of behavioral sensitization to cocaine by NAALADase inhibition","volume":"38","author":"TS Shippenberg","year":"2000","journal-title":"Synapse"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuropharm.2009.06.016","article-title":"N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats","volume":"58","author":"ZX Xi","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1471-4159.2009.06478.x","article-title":"Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2\/3-mediated mechanism","volume":"112","author":"ZX Xi","year":"2010","journal-title":"Journal of neurochemistry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"20101","DOI":"10.1073\/pnas.1209934109","article-title":"Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis","volume":"109","author":"KA Rahn","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1471-4159.2005.03361.x","article-title":"Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury","volume":"95","author":"DJ Bacich","year":"2005","journal-title":"Journal of neurochemistry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2012.11.027","article-title":"NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test","volume":"701","author":"KJ Janczura","year":"2013","journal-title":"European journal of pharmacology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2125.2005.02396.x","article-title":"The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693","volume":"60","author":"JP van der Post","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(00)00519-7","article-title":"Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons","volume":"402","author":"FC Tortella","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/092986712799462630","article-title":"The role of glutamate signaling in pain processes and its regulation by GCP II inhibition","volume":"19","author":"KM Wozniak","journal-title":"Curr Med Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0028-3908(02)00124-7","article-title":"NAALADase (GCP II) inhibition prevents cocaine-kindled seizures","volume":"43","author":"JM Witkin","year":"2002","journal-title":"Neuropharmacology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2005.11.045","article-title":"2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice","volume":"531","author":"JJ Luszczki","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.npp.1300048","article-title":"Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA","volume":"28","author":"P Popik","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpba.2013.08.028","article-title":"Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA)","volume":"88","author":"R Rais","year":"2014","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer","volume":"11","author":"CA Foss","year":"2005","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref47","article-title":"Handbook of Olfaction and Gustation","author":"H Baker","year":"2003"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"SV Dhuria","year":"2009","journal-title":"J Pharm Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717549709051878","article-title":"Delivery of 125I-NGF to the Brain via the Olfactory Route","volume":"4","author":"W Frey","year":"1997","journal-title":"Drug Deliv"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-1998-1102","article-title":"Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway","volume":"1","author":"XQ Chen","year":"1998","journal-title":"J Alzheimers Dis"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/jps.21674","article-title":"Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake","volume":"98","author":"SR Vaka","year":"2009","journal-title":"J Pharm Sci"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"JJ Lochhead","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"NJ Johnson","year":"2010","journal-title":"Mol Pharm"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.111.040782","article-title":"Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration","volume":"39","author":"J Stevens","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.expneurol.2013.03.017","article-title":"Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson&apos;s model","volume":"247","author":"F Febbraro","year":"2013","journal-title":"Exp Neurol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neurobiolaging.2012.05.009","article-title":"Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer&apos;s disease","volume":"34","author":"C Guo","year":"2013","journal-title":"Neurobiol Aging"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.108.149807","article-title":"Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke","volume":"330","author":"LR Hanson","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0957-4166(02)00412-3","article-title":"Synthesis and biological evaluation of (R)- and (S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of glutamate carboxypeptidase II","volume":"13","author":"D Vitharana","year":"2002","journal-title":"Tet Asymm"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jps.2600691215","article-title":"Nasal absorption of propranolol from different dosage forms by rats and dogs","volume":"69","author":"A Hussain","year":"1980","journal-title":"J Pharm Sci"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"RG Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0003-2697(02)00286-5","article-title":"Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay","volume":"310","author":"C Rojas","year":"2002","journal-title":"Analytical biochemistry"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1016\/S0021-9258(18)47823-4","article-title":"Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain","volume":"262","author":"MB Robinson","year":"1987","journal-title":"The Journal of biological chemistry"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"S Craft","year":"2012","journal-title":"Archives of neurology"},{"key":"ref64","first-page":"409","author":"M Gibaldi","year":"1982"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1124\/dmd.112.046821","article-title":"Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo","volume":"40","author":"R Rais","year":"2012","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/jpet.113.205039","article-title":"Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism","volume":"346","author":"JJ Vornov","year":"2013","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.103.050112","article-title":"Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans","volume":"306","author":"J Farrell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1378\/chest.95.3.685","article-title":"Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon","volume":"95","author":"PL Schatz","year":"1989","journal-title":"Chest"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/jps.21604","article-title":"Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system","volume":"98","author":"SV Dhuria","year":"2009","journal-title":"J Pharm Sci"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-beta to the monkey nervous system following intranasal administration","volume":"152","author":"RG Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: new developments and strategies","volume":"7","author":"L Illum","year":"2002","journal-title":"Drug Discov Today"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"L Illum","year":"2003","journal-title":"J Control Release"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1021\/jm300710j","article-title":"Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer","volume":"55","author":"K Graham","year":"2012","journal-title":"J Med Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:46:58Z","timestamp":1652816818000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131861"}},"subtitle":[],"editor":[{"given":"Joseph","family":"Najbauer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131861","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]}}}